STOK
STOK
NASDAQ · Biotechnology

Stoke Therapeutics Inc

$33.08
+0.36 (+1.10%)
As of May 9, 1:31 AM ET ·
Financial Highlights (FY 2026)
Revenue
192.22M
Net Income
-7,178,637
Gross Margin
Profit Margin
-3.7%
Rev Growth
+145.9%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 60.0% 60.0% 60.0%
Operating Margin -11.2% -16.2% -13.4% -15.6%
Profit Margin -3.7% -11.6% -13.8% -12.8%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 192.22M 323.22M 315.22M 266.09M
Gross Profit 193.80M 189.00M 159.55M
Operating Income -21,452,258 -52,228,751 -42,169,219 -41,424,051
Net Income -7,178,637 -37,471,003 -43,595,472 -34,080,935
Gross Margin 60.0% 60.0% 60.0%
Operating Margin -11.2% -16.2% -13.4% -15.6%
Profit Margin -3.7% -11.6% -13.8% -12.8%
Rev Growth +145.9% +14.4% -1.8% +5.4%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 797.73M 940.05M 930.40M
Total Equity 1.37B 1.45B 1.33B
D/E Ratio 0.58 0.65 0.70
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -19,671,813 -52,091,948 -53,358,586 -46,407,378
Free Cash Flow -52,998,459 -42,607,892 -40,994,477